Find your next M&A target
Target Asia + Worldwide M&A projects with our guidance on matching, planning, due diligence & implementation.
Search Seller Projects – ,
The Japanese company's main products include a hybrid battery system, which is compatible with lithium batteries, lead batteries, nickel-metal hydride batteries, etc., and lithium batteries with ultra-high power charge and dischagre. At the same time, it is also developing lithium batteries with ultra-high energy density and high-capacity anode materials. The company's products can be widely used in power storage, power generation systems, industrial batteries, decentralized batteries, electric vehicles and other fields. Since 2014, the total financing scale of the company has been nearly USD 14.9 million (JPY 2 billion). Investors include industrial giants such as Kansai Electric Power and Mitsubishi Materials. The company now seeks financing.
The Japanese company has exclusively developed single-cell genome analysis technology, which is the only effective technology that can obtain the complete genome sequence of microorganisms at present and can be used to serve the leading compound discovery, compound structure optimization, target gene research and other fields involved in the clinical development of pharmaceutical enterprises. The company has 19 employees. The four core founding team members come from well-known universities such as the University of Tokyo, Tokyo University of Agriculture and Technology and Kobe University, and have work experience in international pharmaceutical companies, scientific research institutions, the Boston Consulting Group and other institutions. In 2020, the company obtained B-round financing of USD 5.43 million (JPY 730 million), seeking C-round financing to expand to the Chinese market through technology licencing.
The Turkish company is a power engine parts manufacturer, mainly producing piston, cylinder liner, gas ring and other parts. The company is jointly established by a Turkish local enterprise and the American Federal Mogul. It has famous customers such as Audi, Volvo, General Motors and Ford. It owns a Turkish-listed company. In 2020, the company's revenue is USD 262 million (EUR 250 million). The company has three factories in Istanbul with a total area of nearly 90,000 square meters. The company seeks to sell 50% equity.
The Turkish company is the manufacturer and exporter of worsted wool fabrics. It has a history of 48 years and can produce wool, cashmere, silk fabrics, Lycra, polyester, linen, viscose, cotton fabrics, etc. It has more than 400 customers including Boss, M&S, Ralph Lauren, Zara, H&M and other world-famous brands. Products have been exported to more than 50 countries. The company's sales in 2020 are USD 40 million. It seeks to sell 58% equity.
The Israeli company has the exclusive technology of a real-time clinical quantitative phase microscope. Its products are portable and easy-to-use devices, which can try in real time, stain the same but image pollution-free, and also evaluate DNA fragments. The company has obtained 8 patents for its core technology. The company's unique system uses a desktop workstation and disposable ink cartridge, which can be embedded into the clinical laboratory workflow to select sperm cells according to unified standards. In March 2019, the company completed the seed round financing (and A-round financing commitment). It seeks to set up a Chinese subsidiary to carry out clinical trials and obtain product certification for financing purposes.
The Japanese company manufactures and sells pharmaceutical products mainly for injection and also is entrusted with manufacturing medical supplies. For many years, the company has provided glass ampoule injections for the medical industry in Japan, and at the same time, it has fully met the ready-to-use ("RTU") medical needs by producing unique soft package injections. The company supplies high-quality products to all parts of Japan through its own sales network and other new medicine and generic medicine sales enterprises. In 2020, the company's turnover is about USD 44.5 million (JPY 6 billion). It has 200 employees and more than 32,000 medical institution customers. At present, more than 30 enterprises have entrusted manufacturing business with the company. It realizes the plastic soft package drip product of small volume infusion (50-300ml). The company seeks 100% share sale for USD 44.5 million (JPY 6 billion).
Asia: South Korea
The Korean company's core technology is nanoscale controllable surface coating technology. The company aims to reliably diagnose early human cancer through the highest sensitivity, specificity and lowest detection limit. Through 15 years of research and investment of USD 20 million, the company has completed the R&D of core technology. In vitro diagnosis ("IVD") has been applied and four cardiac lateral flow immunoassay ("LFA") (sidestream analysis) kits have been completed pilotscale experiment. The company has registered patents in 12 countries including the United States and the European Union. The company now seeks investment.
The Yokohama general hospital is a large general hospital with 300 beds. It has internal medicine, psychiartry, pediatric orthopaedics, sports orthopaedics, breast surgery, rheumatology, plastic surgery, gynecology and obstetrics, urology, ophthalmology, otorhinolaryngology, dermatology, dentistry, oral surgery and anethesiology. The hospital is 36 minutes' drive from Haneda Airport. Its opening date is December 1976. Its land for facilities is 20,485 square meters. There are 155 parking spaces in the parking lot and 24 parking spaces for the disabled. The hospital seeks 100% acquisition of USD 133.9 million (JPY 18 billion) or other proportions can be consulted (sales volume is not disclosed).
The Israeli company develops exclusive wound healing technology products, which promote wound healing by using synthetic negatively charged microspheres ("NCM") to stimulate cells involved in wound healing and tissue regeneration. The company's most advanced wound healing products are classified as IIb medical devices in Europe and are manufactured by factories with European Conformity ("CE") mark certification. The company's products are currently sold in the European Union and some Latin American countries, and it plans to enter the American and Canadian markets. Now the company seeks investment.
The Japanese hospital has the following diagnosis and treatment departments: neurosurgery, nephrology, hematology, respiratory, gastroenterology, cardiovascular, endocrinology, pediatrics, surgery, orthopaedics, psychiatry, neurology, dental and oral surgery, rehabilitation, anesthesiology, otorhinolaryngology, urology, ophthalmology and gynecology. The hospital has 296 beds and can undertake medical travel projects. It seeks Chinese partners and to sell 60% or more equity.
Asia: Hong Kong SAR
The Hong Kong company's scope of medical qualifications includes internal medicine, surgery, gynecology and obstetrics, pediatrics, pediatric surgery, children's health care, ophthalmology, otorhinolaryngology, stomatology, dermatology, traditional Chinese medicine inspection, imaging (ultrasound, electrocardiogram ("ECG")). The expiry date of the clinic lease is July 31, 2028. The medical licence is valid until 2026. The company has professional qualifications in ophthalmology, stomatology and dermatology and decoration equipment. It has 24 consulting rooms and 2 dental chairs. It is brand new high-end decorated, which has not yet been opened for use, and is ready for opening at any time. The company is Hong Kong-listed. It seeks the sale of the outpatient department clinic in Foshan or cooperation.
Asia: Hong Kong SAR
The Hong Kong company's scope of medical qualifications includes internal medicine, surgery, gynecology and obstetrics, pediatrics, child health care, ophthalmology, otorhinolaryngology, stomatology, traditional Chinese medicine inspection, and imaging (ultrasound, electrocardiogram ("ECG")). The expiry date of the clinic lease is July 31, 2029. The medical licence is valid till 2025. The company is surrounded by high-end residential and commercial areas. It has ophthalmology and stomatology qualifications and decoration settings. Besides, it has 9 consulting rooms, complete treatment room, laboratory and ultrasound room. It is Hong Kong-listed. The company seeks the sale of the clinic in Foshan or cooperation.
Enquire for more information about our services, and how we can help solve challenges for your organizationContact Us